Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult ≥18 years with confirmed HIV-1 or 2 infection~* Infection with HCV genotype 1 or 4 only, confirmed and with detectable HCV-RNA ≥ 1000 IU/mL at screening.~* Null responders to a previous treatment with Peginterferon and Ribavirin, defined by a fall of less than 2 log10 IU/ml HCV-RNA from baseline to week 12.~* Stable antiretroviral treatment for \> 1 month at screening containing any of the following drugs: Raltegravir, Enfuvirtide, Tenofovir-Emtricitabine, Abacavir-Lamivudine.~* CD4 \> 200 /mm3 and \> 15% at screening~* HIV-RNA \< 400 copies/mL from ≥ 3 months at screening~* Any liver fibrosis stage,~* with the assessment of the presence or not of cirrhosis at screening:~  * previous liver biopsy exhibiting cirrhosis lesions (METAVIR F4), and/or~ * significant liver biopsy (cumulative length ≥ 15 mm and ≥ 6 portal spaces), within 18 months and after the end of last HCV treatment, and/or~ * significant and reliable liver stiffness assessment (Fibroscan®) within 6 months (at least 10 measures with IQR less then 25% of the mean value and a success rate of at least 80%)~* cirrhosis being defined as a METAVIR score F4 on liver biopsy and/or liver elastometry ≥ 15 kPa~* the proportion of patients with cirrhosis (METAVIR F4) is limited to 50% of all patients.~* Body weight ≥ 40 kg and ≤125 kg~* Male patients, female patients with child-bearing potential and their heterosexual partners must use adequate contraception from 1 month before initiation of treatment to 7 months following the end of treatment for men and to 4 months following the end of treatment for women.~* Informed and signed consent~* For participating patients, informed and signed consent for the pharmacokinetic sub-study~* Patients affiliated to the National Health Insurance or covered by Universal Medical Coverage~* For the first 12 patients included (who will participate to the pharmacological substudy): stable antiretroviral treatment for \> 1 month at screening, with Raltegravir+ Emtricitabine+ Tenofovir~Exclusion Criteria:~* CHILD B and C cirrhosis, past history of decompensated cirrhosis. Patients with CHILD A cirrhosis must demonstrate the absence of significant oesophageal varices (Stages 2-3) on an upper gastrointestinal endoscopy ≤ 12 months~* Positive HBs antigenemia with HBV DNA \> 1000 IU/ml((if positive AgHBs with HBV DNA ≤ 1000 IU/mL, patient will be included provided it is treated with Ténofovir)~* Pregnant women, breast-feeding women~* Refusal of adequate contraception~* Contra-indication to Ribavirin, including hypersensitivity reaction to Ribavirin~* Contra-indication to Peginterferon, including psychiatric contra-indications. Patients with significant psychiatric past history, notably severe depression requiring hospitalization or suicide attempt, cannot be included unless they undergo a psychiatric evaluation and obtain a specific authorization for the use of interferon.~* Premature discontinuation (during the first six months) of a previous HCV treatment for toxicity. Patients who have stopped a previous treatment for severe anaemia or neutropenia can enter the study if erythropoietin or granulocyte growth factor had not been used during the previous treatment~* Previous HCV therapy including HCV NS3 protease inhibitor~* Severe pre-existing cardiac or pulmonary disease~* History of organ transplant~* Acute CDC stage C opportunistic infection occurring within the previouW6 months~* Any active malignant disease including hepatocellular carcinoma for which a specific assessment is required at screening~* Alcohol intake that may represent an obstacle for the participation of the subject in the study~* Substance abuse that may represent an obstacle for the participation of the subject in the study. Stabilized patients included in a substitution program can participate in the study~* Patients with previous observance problem unable to observe the study procedures~* Participation in another clinical trial within the previous 30 days~* Haemoglobin \< 90 g/L~* Platelets \< 50 000 /mm3~* Neutrophil count \< 750 /mm3~* Renal insufficiency defined by an estimated Glomerular Filtration Rate \< 50 mL/mn (MDRD equation)~* Absence of antiretroviral treatment or antiretroviral treatment different from the authorized combinations~* Associated medication likely to interfere with any of the study drugs such as CPY3A4 inducers (rifampin, Millepertuis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a (Type: EXPERIMENTAL): * Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~* Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete